No further trading or reporting obligations remain; the stock is no longer publicly listed. Monitor for final distributions to former shareholders, if any.
Price Chart
Executive Summary
Day One Biopharmaceuticals filed Form 15 to terminate its SEC registration and suspend reporting obligations, effective May 4, 2026, following its acquisition by Servier Pharmaceuticals. The company reports only one holder of record, confirming the take-private transaction is complete.
Key Facts
- Filed Form 15-12G to terminate registration under Section 12(g) of the Exchange Act.
- Approximate number of holders of record: One.
- Follows Nasdaq delisting (Form 25) filed April 23, 2026, and acquisition by Servier Pharmaceuticals.
Financial Impact
Not specified
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 15-12G Filing (Primary) | 0001193125-26-202385 |
| Document: 0001193125-26-202385-index-headers.html | 0001193125-26-202385 |
| Document: 0001193125-26-202385-index.html | 0001193125-26-202385 |
| Document: 0001193125-26-202385.txt | 0001193125-26-202385 |
Track record
6 reports on DAWN
The track record builds as more bullish or bearish reports settle.
Filters
- May 4, 202628w ago 15-12G Neutral 5/10 Viewing No price data
- Apr 23, 202629w ago 25-NSE Neutral 9/10 Entry $21.53 No price data
- Apr 23, 202629w ago 8-K Neutral 9/10 Entry $21.53 No price data
- Apr 17, 202630w ago 10-K/A Neutral 4/10 Entry $21.48 No price data
- Mar 6, 202636w ago Press Release Bullish 9/10 Entry $21.20 to $21.46 ▲ +1.23% +3.27% vs SPY
- Feb 24, 202637w ago 8-K Bullish 8/10 Entry $10.92 to $21.37 ▲ +95.79% +101.02% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers